Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Armata Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
ARMP
NYSE American
2836
www.armatapharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Armata Pharmaceuticals, Inc.
Bacteriophage Therapy - Global Strategic Business Report 2026: Capture the $1.6 Billion 2032 Market with Adaptive Phage Therapeutics, Armata Pharmaceuticals, BiomX, and Locus Biosciences
- Nov 19th, 2026 8:17 am
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Beats Revenue Estimates
- Nov 12th, 2026 3:05 pm
Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate Update
- Nov 12th, 2026 2:05 pm
Liquidia Corporation (LQDA) Q3 Earnings and Revenues Beat Estimates
- Nov 10th, 2026 4:40 am
Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates
- Nov 5th, 2026 2:45 pm
Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue Estimates
- Nov 2nd, 2026 8:20 am
Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States
- Oct 7th, 2026 5:00 am
Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development
- Sep 23rd, 2026 5:00 am
Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates
- Sep 21st, 2026 5:00 am
Armata Pharmaceuticals Shares Rise 8% After FDA Grants AP-SA02 Breakthrough Therapy Designation
- Sep 14th, 2026 7:34 am
Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02
- Sep 14th, 2026 5:00 am
Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Sep 10th, 2026 5:00 am
Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials
- Sep 3rd, 2026 5:00 am
Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
- Aug 13th, 2026 8:31 am
Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update
- Aug 12th, 2026 2:05 pm
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
- Jul 21st, 2026 5:05 am
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02
- Jul 20th, 2026 5:00 am
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia
- Jul 13th, 2026 5:00 am
Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support AP-SA02
- Jun 23rd, 2026 5:00 am
Here’s Why Armata Pharmaceuticals Inc. (ARMP) is a High Growth Micro-Cap Stock to Buy?
- Jun 19th, 2026 12:18 pm
Scroll